
Release date: 2026-02-25 17:17:22 Article From: Lucius Laos Recommended: 11
Lumykras (generic name: Sotorasib) is a prescription targeted therapy drug for non-small cell lung cancer (NSCLC) that targets a specific gene mutation (KRAS G12C). Its price is influenced by factors such as strength/specification, purchasing channel, and medical insurance policies. The exact cost should be confirmed with the actual selling price at hospitals or authorized pharmacies.
Strength/Specification Differences: The total price can be affected by different dosages (e.g., 120mg/tablet x 240 tablets) or pack sizes.
Medical Insurance Policies: Patient out-of-pocket costs may be reduced if the drug is covered by medical insurance in some regions.
Purchasing Channels: Prices may vary between hospitals, designated pharmacies, or overseas sources. Medication must be obtained through legal and legitimate channels.
Applicable Population: Strictly limited to patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been confirmed to have the KRAS G12C mutation through testing.
Administration: Taken orally once daily. Dosage adjustments must be strictly followed as prescribed by a physician. Do not adjust the dose or stop taking the medication on your own.
Side Effects: Common side effects include diarrhea, elevated liver enzymes, and fatigue. Seek immediate medical attention if side effects are severe.
Use as Prescribed: A prescription must be issued by an oncologist after evaluating genetic test results. Do not purchase or take this medication on your own.
Regular Monitoring: Liver function, complete blood counts, and other indicators need to be monitored during treatment.
Medical Guidance: Contact your primary physician immediately if you experience difficulty breathing, severe skin rash, or persistent vomiting.
Consult the hospital pharmacy directly by presenting your prescription and genetic test report.
Check local reimbursement policies through platforms like the National Healthcare Security Platform (if applicable in your region).
Contact legitimate oncology pharmacies or authorized drug delivery platforms to confirm availability and current pricing.
Lucius Pharmaceuticals Sotorasib must be used under the full supervision of a physician. Patients should not make decisions about using this drug based solely on online information. It is strongly recommended to complete the testing, prescription, and medication procurement processes throughStandard medical institution to ensure treatment safety.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1342025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3852024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1332025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1412025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1342025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1562025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1402025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1402025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: